AM-2394

Research use only, not for human use.

A potent, orally bioavailable Glucokinase (GK) activator with EC50 of 60 nM.

A potent, orally bioavailable Glucokinase (GK) activator with EC50 of 60 nM; increases the affinity of GK for glucose by 10-fold, exhibits moderate clearance and good oral bioavailability in multiple animal models; lowers glucose excursion in an ob/ob mouse model of diabetes.Diabetes Preclinical.

——

AM-2394, a structurally distinct glucokinase activator that displays a robust reduction in plasma glucose during an oral glucose tolerance test (OGTT) in ob/ob mice at a dose of 3 mg/kg. AM-2394 increases the affinity of glucokinase (GK) for glucose by approximately 10-fold, exhibits moderate clearance and good oral bioavailability in multiple animal models, and lowers glucose excursion following an oral glucose tolerance test in an ob/ob mouse model of diabetes. AM-2394 exhibits good-to-moderate cross species plasma clearance, volume of distribution, and oral bioavailability, allowing for further evaluation in animal models.

AM2394

Cytoskeleton/Cell Adhesion Molecules

Glucokinase

glucokinase

Metabolic Disease

Diabetes

1442684-77-6

423.465

C22H25N5O4

>98% (HPLC)

DMSO: ≥ 30 mg/mL

O=C(NC)NC1=CC(OC2=CC(C)=CN=C2)=C(C3=CC=C(OCC(C)(O)C)N=C3)C=N1

Urea, N-[6'-(2-hydroxy-2-methylpropoxy)-4-[(5-methyl-3-pyridinyl)oxy][3,3'-bipyridin]-6-yl]-N'-methyl-

(-20℃)

With Ice Pack

≥ 2 years